Adjuvant chemotherapy for early breast cancer

Optimal use of epirubicin

Stefan Glück

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets, including situations where use of dose-dense and/or dose-intense protocols may provide additional benefits and where combinations including taxanes and/or trastuzumab may provide increased efficacy. Epirubicin also has a distinct safety profile compared to doxorubicin with regard to cardiotoxicity. In order to optimize treatment benefits and safety concerns for node-positive, node-negative and HER-2-positive patients as well as patients receiving neoadjuvant therapy and elderly patients it is worthwhile to consider the potential benefits of epirubicin.

Original languageEnglish
Pages (from-to)780-791
Number of pages12
JournalOncologist
Volume10
Issue number10
DOIs
StatePublished - Nov 1 2005
Externally publishedYes

Fingerprint

Epirubicin
Adjuvant Chemotherapy
Breast Neoplasms
Safety
Taxoids
Neoadjuvant Therapy
Anthracyclines
United States Food and Drug Administration
Combination Drug Therapy
Doxorubicin
Canada
Therapeutics

Keywords

  • Adjuvant treatment
  • Anthracyclines
  • Doxorubicin
  • Epirubicin
  • Neoadjuvant treatment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Adjuvant chemotherapy for early breast cancer : Optimal use of epirubicin. / Glück, Stefan.

In: Oncologist, Vol. 10, No. 10, 01.11.2005, p. 780-791.

Research output: Contribution to journalArticle

Glück, Stefan. / Adjuvant chemotherapy for early breast cancer : Optimal use of epirubicin. In: Oncologist. 2005 ; Vol. 10, No. 10. pp. 780-791.
@article{34fe56b7119a48e18de09affb46e7746,
title = "Adjuvant chemotherapy for early breast cancer: Optimal use of epirubicin",
abstract = "Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets, including situations where use of dose-dense and/or dose-intense protocols may provide additional benefits and where combinations including taxanes and/or trastuzumab may provide increased efficacy. Epirubicin also has a distinct safety profile compared to doxorubicin with regard to cardiotoxicity. In order to optimize treatment benefits and safety concerns for node-positive, node-negative and HER-2-positive patients as well as patients receiving neoadjuvant therapy and elderly patients it is worthwhile to consider the potential benefits of epirubicin.",
keywords = "Adjuvant treatment, Anthracyclines, Doxorubicin, Epirubicin, Neoadjuvant treatment",
author = "Stefan Gl{\"u}ck",
year = "2005",
month = "11",
day = "1",
doi = "10.1634/theoncologist.10-10-780",
language = "English",
volume = "10",
pages = "780--791",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "10",

}

TY - JOUR

T1 - Adjuvant chemotherapy for early breast cancer

T2 - Optimal use of epirubicin

AU - Glück, Stefan

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets, including situations where use of dose-dense and/or dose-intense protocols may provide additional benefits and where combinations including taxanes and/or trastuzumab may provide increased efficacy. Epirubicin also has a distinct safety profile compared to doxorubicin with regard to cardiotoxicity. In order to optimize treatment benefits and safety concerns for node-positive, node-negative and HER-2-positive patients as well as patients receiving neoadjuvant therapy and elderly patients it is worthwhile to consider the potential benefits of epirubicin.

AB - Anthracyclines are central components of adjuvant combination chemotherapy regimens for early breast cancer. Epirubicin is underutilized for this indication in the United States, where it was approved by the Food and Drug Administration in 1999, compared to Europe and Canada, where it gained approval in 1980. Use of epirubicin offers advantages in specific treatment settings and patient subsets, including situations where use of dose-dense and/or dose-intense protocols may provide additional benefits and where combinations including taxanes and/or trastuzumab may provide increased efficacy. Epirubicin also has a distinct safety profile compared to doxorubicin with regard to cardiotoxicity. In order to optimize treatment benefits and safety concerns for node-positive, node-negative and HER-2-positive patients as well as patients receiving neoadjuvant therapy and elderly patients it is worthwhile to consider the potential benefits of epirubicin.

KW - Adjuvant treatment

KW - Anthracyclines

KW - Doxorubicin

KW - Epirubicin

KW - Neoadjuvant treatment

UR - http://www.scopus.com/inward/record.url?scp=31444432285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31444432285&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.10-10-780

DO - 10.1634/theoncologist.10-10-780

M3 - Article

VL - 10

SP - 780

EP - 791

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 10

ER -